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The binding domain of Duffy protein (DBP-II) is a leading
vaccine candidate of Plasmodium vivax. In order to
develop a successful vivax malaria vaccine based on DBP-
II, the antigenic diversity and also naturally occurring
functional antibodies to different PvDBP-II variant types
in the various populations must be known. To define
whether the polymorphisms in PvDBP-II influenced the
nature of functional antibody responses, this investigation
was designed to evaluate naturally acquired antibodies to
five circulating variant forms of DBP-II antigens in
infected individuals with P. vivax living in hypoendemic
areas in Iran. Sequence diversity of pvdbp-II gene was per-
formed in 63 Iranian P. vivax isolates collected during
2008-2012. The sequencing analysis showed twenty two
single nucleotide polymorphisms in PvDBP-II, resulting in
16 different haplotypes among the Iranian P. vivax isolates.
Five of 16 genetically distinct variants were expressed in E.
coli, and anti-DBP-II responses were measured in P.
vivax-infected individuals (n = 202). Also, by performing
immune-depletion ELISA experiments, antibody responses
to the conserved sites of all five allelic forms were evalu-
ated using the corresponding and non-corresponding
patients’ sera (n = 20). ELISA results revealed that natu-
rally acquired anti-PvDBP-II IgG were recognized all five
expressed variant forms with no statistically difference
(P > 0.05, Cochran’s Q test). The antibody depletion
experiments also showed presence of the cross-reactive
antibody responses to heterologous variants of PvDBP-II
in Iranian individuals who were infected with distinct alle-
lic forms of the PvDBP-II. Finally, all five examined variant
forms of DBP-II were expressed transiently on the surface
of COS-7 cells to determine whether people exposed to
vivax malaria acquire antibodies that have the ability to
block erythrocyte cytoadherence to PvDBP-II. The anti-
DBP-II IgG block heterologous and homologous expressed
DBP-II function, indicating that the protective immunity
against PvDBP-II binding is not strain specific. In conclu-
sion, the present results indicate that the single variant of
PvDBP-II is adequate to be included in a PvDBP-II-based
vaccine.
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